Compare Diamondback Energy Inc (FANG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Diamondback Energy Inc is far larger — about 5.3× State Street SPDR S&P Biotech ETF's market cap, and Diamondback Energy Inc pays a 2.3% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FANG | XBI | |
|---|---|---|
Market Cap | $53.67B | $10.11B |
Volume | 2,250,644 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $213.69 | $169.55 |
52-Week Low | $137.29 | $104.99 |
Typical Hold Time | 69 Days | 38 Days |
Enterprise Value | $65.83B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.68, up 3.96% today, with strong analyst support (90.57% buy rating) and a $231.77 consensus price target. The stock shows bullish technical momentum above key support at $189, while fundamentals reveal robust revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent Q2 2026 earnings beat expectations at $6.48 EPS, and the company maintains solid cash flow generation with $8.76B from operations in 2025.
FANG presents a compelling growth opportunity with Permian Basin dominance and positive earnings momentum, but investors face risks from oil price volatility and insider selling. The stock's current valuation at 36.51 P/E requires sustained execution to justify upside, while technical indicators suggest near-term resistance at $193-197 levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
